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Abstract 
Background: Prostate brachytherapy consists in placing radioactive seeds for tumour 
destruction under transrectal ultrasound imaging (TRUS) control. It requires prostate 
delineation from the images for dose planning. Because ultrasound imaging is patient and 
operator-dependant, we have proposed to fuse MRI data to TRUS data to make image 
processing more reliable. Technical accuracy of this approach has already been evaluated. 
Methods: We present work in progress concerning the evaluation of the approach from the 
dosimetry viewpoint. The objective is to determine which impact this system may have on the 
treatment of the patient. Dose planning is performed from initial TRUS prostate contours and 
evaluated on contours modified by data fusion.  
Results: For the 8 patients included, we demonstrate that TRUS prostate volume is most often 
underestimated and that dose is overestimated in a correlated way. However, dose constraints 
are still verified for those 8 patients. 
Conclusions: This confirms our initial hypothesis.  
 
 
1. Introduction 
Prostate cancer is one of the most common malignancy among men. An estimated 543000 
cases and 204000 deaths were attributed to prostate cancer in 2000 [1]. Its detection is based 
on digital rectal examination (DRE) and Prostate Specific Antigen (PSA) rating and is 
confirmed through the anatomo-pathologic analysis of biopsies. Several treatments may be 
proposed to the patient suffering from localized prostate cancer (T1c-T2b N0 M0, UICC 
2002). One of them is prostate brachytherapy which consists in placing permanent radioactive 
seeds, most often I125, inside the prostate thanks to needles passing through the perineum. 
Most often treatment planning and needle placement rely on the intensive use of transrectal 
ultrasound imaging (TRUS). Parallel transverse images are acquired with constant inter-slice 
distance thanks to the use of a stepper. Needle insertion through the perinea is made easier 
thanks to a grid rigidly connected to the TRUS probe (see figure 1).  
 
Fig. 1: US-guided transperineal brachytherapy operating principles.  
From http://www.uropage.com/index.htm  
 
Prostate volume study is a critical step for treatment planning; it allows selecting precisely the 
number of seeds to be inserted and their position in the gland in order to obtain a predefined 
dose distribution (see section 3). Traditionally, this volume definition is manually performed 
by the clinician from TRUS images (either pre-operatively or intra-operatively). But it is well 
known that ultrasonic image quality is highly variable from patient to patient and that organ 
delineation varies from user to user and for a same user, from session to session. In this 
context, Magnetic Resonance Imaging (MRI) has a great potential. In very few centres, 
radioactive seeds are implanted inside an open interventional MR machine [2,3]. Robots may 
also be used in conjunction to MRI imaging for improved accuracy and increased possible 
trajectories [4]. Often such robots or systems are jointly designed for biopsy and 
brachytherapy since both gestures basically involve needle insertion into the prostate under 
TRUS control. 
 
In this project, we chose to bring the MR virtually in the Operating Room (OR) by TRUS/MRI 
data fusion in order to help the clinician for treatment planning without requiring the presence 
of both the patient and the implantation team in the MRI room. A similar idea was used by [5] 
in the context of TRUS-guided prostate biopsies. However, where [5] uses rigid registration 
of 6 anatomical landmarks, the present work makes use of a combined rigid and elastic 
surface registration.  
 
Having demonstrated the accuracy of data fusion (see [6]), a study has been undertaken for 
evaluating the impact of MRI/TRUS data fusion on dose distribution. This on-going work is 
described in the paper. Section 2 presents the method and summarizes preliminary results. 
Section 3 introduces dose constraints to be satisfied. Section 4 describes the evaluation 
protocol. Results are given in section 5 and discussed in section 6. 
 
 
2. MRI/US data fusion: principles and previous results 
The developed system is based on combined rigid and elastic surface registration. Pre-
operatively, a MRI acquisition of the patient prostate is performed; three orthogonal T2 TSE 
volumes are obtained using an endorectal coil and the prostate contours are segmented jointly 
on the three volumes. This gives a set of points SMRI defined in a single referential RMRI. Intra-
operatively, TRUS axial slices are collected and manually segmented by the urologist as in 
the conventional procedure and this results in a sparser intra-operative 3D prostate model 
STRUS  defined in a referential RTRUS; as mentioned above, the axial contours are necessary for 
dose simulation and planning. Pseudo-sagital slices may also be acquired and segmented and 
then merged to the data resulting from the axial acquisition (cf. figure 2). The objective of 
registration is to determine the transform between RTRUS and RMRI allowing the optimal 
superimposition of STRUS and SMRI. Registration determines prostate motion between the two 
acquisitions as well as prostate deformations. A pre-registration consisting in superimposing 
the centres of gravity of STRUS and SMRI initializes the unknown transform. From this initial 
estimate, rotation and translation parameters between data sets as well as local deformations 
or distortions are determined. The method is derived from the octree-spline elastic registration 
described in [7]. It makes use of an adaptive, hierarchical and regularized free-form 
deformation of one volume to the other coordinate system. The optimization stage is based on 
the Levenberg-Marquadt minimization procedure. The result is a 3-D function f transforming 
any ultrasound data point in RTRUS to the corresponding MRI point in RMRI.  
 
  
Fig. 2.  
MRI/TRUS fusion for brachytherapy: (left) two of the axial and pseudo-sagital TRUS images (middle) 3D TRUS 
reconstruction (right) composite image produced after MRI/TRUS elastic registration: for each axial TRUS 
image the corresponding MRI data are computed – the green cursor enable motion in the modalities. 
 
 
After MRI/TRUS surface-based elastic registration, for each initial TRUS image, a new 
composite image divided in 4 quadrants (2 TRUS quadrants and 2 MRI ones) is computed 
(see figure 2).  The pixel intensity I at coordinates (u,v) of the composite image associated to 
the nth TRUS image is obtained as follows: 
- I (u, v, n) = TRUS (u, v, n) in the TRUS quadrant where TRUS (u, v, n) is the pixel 
intensity at coordinates (u, v) in the nth TRUS image 
- I (u, v, n) = MRI (x, y, z) where (x, y, z) = f (u, v, n) in the MRI quadrants; since x, y 
and z have real values MRI (x, y, z) is obtained by interpolating neighbour intensity values in 
the MRI volume. 
 
The user can interactively modify the composite image by moving the cross cursor dividing 
this image; this enables exploring the prostate jointly in the MRI and TRUS data. This may 
result in modifying locally the TRUS segmentations of the axial slices when MRI data make 
prostate delineation easier. In the following prostate contours obtained after MRI/TRUS data 
fusion are named “MRI+US contours” whilst original contours are named “US contours”. 
More generally, all data or measurements obtained after MRI/TRUS fusion are named 
“MRI+US xxx” where measurements from US contours are named “US xxx”. 
 
[6] presents a technical evaluation of the system on phantom and patient data. Both rigid and 
elastic registrations were evaluated; elastic registration which demonstrated higher accuracy is 
briefly reported below (see table 1). It was measured both in terms of residual distance 
between matched surfaces and using TRE (Target Registration Error) evaluated from the 
urethra which does not participate to matched data. Residual surface distance was measured 
for 11 patients; TRE was evaluated for only 4 of them who were equipped with an endo-
urethral probe making the urethra fully visible on TRUS and MRI modalities. 
 
 Residual surface distance (mm) TRE (mm) 
Phantom 1.07±0.41 1.57±0.62 
Patients 1.11±0.54 2.07±1.57 
Table 1: Accuracy evaluation of elastic registration (see [6] for more details). 
 
Another aspect of the evaluation concerned prostate volume measurements from TRUS 
images with and without data fusion. Because the number of seeds depends on the prostate 
volume, modification in the latter may have a significant clinical impact. This preliminary 
study showed that apex and base US slices where often added to the segmented data when 
MRI information was fused to US data. For the 11 patients involved in the trial, the MRI+US 
gland volume was higher than the US volume; for elastic registration this volume increase 
was in average 15.86(±13.57)% of the US volume. Underestimating the prostate volume 
could result in delivering less radiation than expected to the target.  Based on those 
preliminary observations, the project has been then to analyze MRI/TRUS fusion in prostate 
brachytherapy from the viewpoint of dose delivery to the organs.  
 
 
3. Dose constraints 
The objective is to evaluate the potential influence of TRUS/MRI registration on the treatment 
of the patient. In the Grenoble Hospital, the target dose for treatment of the prostate is 160Gy. 
The corresponding dose constraint is to deliver between 160Gy and 180Gy to 90% of the 
volume of the gland. Maximum dose constraints are also specified for the anatomical 
structures at risks: urethra and rectum. At least 30% of the urethra volume must receive less 
than 240Gy (150% of the target dose); a dose greater to 160Gy must not be delivered to more 
than 1.3cc of the rectum. Finally 90% of the rectum volume must receive less than 80Gy.  
 
One common way to represent dose distribution is the so-called Dose Volume Histogram 
(DVH). The x coordinate represents a dose (percentage of total dose or absolute value in Gy) 
and the y coordinate denotes a volume (percentage of total volume or absolute value in cc). A 
point (x,y) on the curve associated to an organ or to an anatomical structure means for 
instance: y% of the organ volume receives at least x Gy. The constraints listed in the previous 
paragraph can be summarized in figure 3. D90 is the maximum dose received by 90% of the 
organ. 
 
 
Fig. 3.  
Dose Volume Histogram and treatment constraints 
 
 
4. Proposed evaluation protocol 
At this stage of the study the patient is treated in the conventional way. During the 
conventional procedure, data are collected and stored in the DICOM-RT format including US 
images, segmented contours and treatment plan. After patient treatment, those data are post-
processed. MRI data are fused to TRUS information and segmented MRI contours are 
mapped onto TRUS images using the computed transfer function f. This gives a new set of 
contours in the US images; the dosimetric plan is evaluated for those two volumes: the US 
volume and the MRI+US volume.  
 
Up to now 8 patients have been included in this protocol which has been approved by the 
hospital ethical committee; we plan to include a total of 16 patients. Different parameters have 
been examined and compared: 
- prostate volumes, 
- percentage of prostate volumes in the 140, 160 and 180Gy isodoses, 
- values of D90 in the prostate. 
 
5. Results 
Table 2 presents the prostate volume analysis with and without data fusion for the 8 patients. 
As can be seen the MRI+US volume is greater than the US volume for 6 of the 8 patients. 
Most volume differences are in the apex and base regions of the prostate for which TRUS 
images are often difficult to interpret. For 3 of those 6 patients, the increase of volume 
exceeds 10% of the initial US volume. Since the number of patients is rather small, a non 
parametric test has been selected. A Wilcoxon test has been applied to those paired 
measurements which demonstrates that the two series of measurements are significantly 
different (p=0.05).  
 
Patient 
number 
US volume (cc) MRI+US volume 
(cc) 
Diff = MRI+US 
volume - US 
volume (cc) 
100 Diff / US 
volume (%) 
1 24,12 23,05 -1,07 -4,43 
2 21,22 22,91 1,684 7,93 
3 44,21 50,53 6,32 14,29 
4 26,74 28,72 1,98 7,40 
5 29,52 32,66 3,14 10,63 
6 31,09 35,05 3,96 12,73 
7 35,93 38,91 2,98 8,29 
8 36,57 35,64 -0,93 -2,54 
Mean value 31,17 33,43 2,25 6,79 
Stand. dev. 7,49 9,03 2,45 6,79 
Table 2: Prostate volume analysis 
 
The “isodose 160” encloses the volume of the prostate that receives at least 160Gy, the target 
dose. Table 3 presents the “isodose 160” analysis with and without data fusion. As can be 
seen, the MRI+US “isodose 160” includes less prostate volume for 7 of the 8 patients. 
However, all cases still verify the constraint of having 90% of the prostate receiving more 
than 160Gy. Patient 5 comes close to this inferior limit of the dose. A Wilcoxon test has been 
also applied to those paired measurements demonstrating that the two series of measurements 
are significantly different (p=0.05). 
 
Patient 
number 
US “isodose 160” 
(% of prostate 
volume) 
MRI+US 
“isodose 160” 
(%) 
Diff = MRI+US 
isodose - US 
isodose (%) 
100 Diff / US 
isodose (%) 
1 96,67 96,76 0,09 0,09 
2 98,08 93,7 -4,38 -4,46 
3 98 91,34 -6,66 -6,79 
4 98,39 95,49 -2,9 -2,94 
5 97,41 90,5 -6,91 -7,09 
6 99,43 93,18 -6,25 -6,28 
7 97,82 92,41 -5,41 -5,53 
8 98,63 97,49 -1,14 -1,15 
Mean value 98,05 93,85 -4,19 -4,27 
Stand. dev. 0,82 2,52 2,63 2,68 
Table 3: “Isodose 160” analysis 
 
As expected those dose modifications are correlated to volume ones (Spearman coefficient: 
0.904 greater than Spearman threshold=0.88 for n=8, alpha risk=0.01); this is quite visible on 
figure 4. 
 
Fig. 4. 
Correlation between volume difference (x) and dose difference (y)
 
D90 is the maximum dose received by 90% of the prostate. As mentioned below, this dose 
must be more than 160Gy and less than 180Gy. Table 4 presents a comparison of estimates of 
the D90 (since the exact value of D90 is difficult to get) with and without data fusion. The 
exact volume corresponding to the dose is mentioned near the dose value. As can be seen, the 
MRI+US D90 is smaller for 7 of the 8 patients. However, all cases still verify the constraints 
of having 160Gy<D90<180Gy. Patient 5 comes close to this inferior limit of the dose. A test 
of Wilcoxon has been applied to those paired measurements demonstrating that the two series 
of measurements are significantly different (p=0.05). 
 
Patient 
number 
US D90 (vol)  
(Gy (%)) 
MRI+US D90 (vol) 
(Gy (%)) 
Diff = MRI+US 
D90 - US D90 
(Gy) 
100 Diff / US 
D90 (%) 
1 175 (89,58) 175 (90,09) 0 0 
2 175 (89,32) 165 (92,25) 10 5,71 
3 175 (88,44) 165 (89,89) 10 5,71 
4 179,2 (90,4) 172,8 (90,44) 6,4 3,57 
5 172,8 (90,71) 160 (90,5) 12,8 7,40 
6 174,4 (90,33) 166,4 (90,45) 8 4,58 
7 174,4 (90,81) 164,8 (90,27) 9,6 5,50 
8 174,4 (90,24) 172,8 (90,07) 1,6 0,91 
Mean value 175,02 (89,97) 167,72 (90,49) 7,3 4,17 
Stand. dev. 1,83 (0,8) 5,19 (0,74) 4,42 2,55 
Table 4: D90 analysis 
 
Figure 5 presents the comparative DVH of patient number 7. 
 
 
Fig.5. 
Comparative DVH for patient number 7 
 
For patient 3, for whom the volume difference is the greatest, figure 6 illustrates dosimetry on 
the apex (left and middle) and base (right) prostate TRUS images. MRI+US contours are 
presented in red; US contours are brown; yellow points represent planned seed positions; 
green and pink contours respectively correspond to 160Gy and 240Gy isodoses. The two apex 
images clearly show a potential underdosage of the prostate.  
 
Fig. 6. 
Visualisation of MRI+US and US contours plus isodoses on apex (left; middle) and base (right) TRUS images. 
 
 
6. Discussion 
Results presented below although still partial confirm the hypothesis that TRUS image 
delineation often underestimates prostate volume due to poor readability of apex and base 
slices and that it results in overestimating the dose delivered to the patient.  
 
We observed that volume difference for those 8 patients was smaller than for the 11 patients 
having been included in the first evaluation. On average this volume difference was 15.86% 
for the 11 first patients instead of 6.79% for the 8 patients included in this work. Since the 
protocols were slightly different this does not allow a too direct comparison of numbers. 
Meanwhile, those differences may be explained partly by a side effect of this study having 
probably resulted in a learning curve associated to prostate TRUS delineation; indeed when 
the work on MRI/TRUS fusion began, the implantation team (urologist, radiation oncologist 
and radiophysicist) had still a rather low experience of prostate brachytherapy – implantations 
began in July 2001. We suppose that post-processing of data and comparison of US data to 
MRI ones increased the level of knowledge of the urologist who delineates the prostate on the 
TRUS images.  
 
From the dosimetry point of view experiments confirm that the almost systematic 
underestimation of prostate volume results in a significant decrease of dose delivered to the 
prostate. However, prostate dose constraints are still verified on MRI+US contours for those 8 
patients. This has to be confirmed on a larger number of patients since some preliminary 
evaluation exhibited cases where the D90 was substantially lower than expected (see [6]). 
This has also to be confirmed on organs at risk but this requires software modification which 
is in progress.  
 
The overestimation of delivered dose has probably a limited effect in terms of treatment 
quality and therapeutic effects. Nevertheless the implantation team is very enthusiastic about 
using this system since they expect an improved comfort for image processing and an 
increased confidence in the planning.  
 
One can see on figure 7 another use of the system where isodoses corresponding to planning 
from the TRUS images are mapped to the MRI data. The visual validation of those isodoses 
from MRI data is apparently much easier than the direct evaluation from TRUS images since 
anatomical substructures are more visible on MRI than on TRUS data. This point has not yet 
been tested extensively but clinicians and physicists reacted very positively to such a 
possibility. One prospective development of this project could be to perform the planning 
directly on MRI data and to transfer this planning to the OR thanks to MRI/TRUS data fusion. 
 
  
Fig. 7.  
Dose visual assessment (left) from TRUS image (middle and right) from MRI axial and sagital views after MRI/TRUS 
data fusion. For middle and right views: orange=150Gy isodose; blue=180Gy isodose; red=240Gy isodose. 
 
 
7. Conclusion 
We have presented on-going work concerning the impact of data fusion on dose distribution 
for prostate brachytherapy. Dose is systematically overestimated due to underestimation of 
the TRUS prostate volume although the treatment still verifies dose constraints on the prostate 
for the 8 patients already included in this trial. Clinically using MRI/TRUS data fusion would 
result in a more reliable delineation of the prostate making real dose delivered to the prostate 
certainly closer to the planned dose. Further work remains concerning the evaluation of dose 
distribution on urethra and rectum. However, obtained results are already encouraging. From 
those preliminary results it is likely that MRI/TRUS data fusion could facilitate treatment 
planning and improve quality assessment.  
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